{{Rsnum
|rsid=4787484
|Gene=SEZ6L2
|Chromosome=16
|position=29895225
|Orientation=plus
|GMAF=0.2888
|Gene_s=SEZ6L2
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 38.9 | 49.6 | 11.5
| HCB | 35.0 | 45.3 | 19.7
| JPT | 50.4 | 43.4 | 6.2
| YRI | 79.6 | 19.7 | 0.7
| ASW | 70.2 | 28.1 | 1.8
| CHB | 35.0 | 45.3 | 19.7
| CHD | 25.7 | 55.0 | 19.3
| GIH | 69.3 | 29.7 | 1.0
| LWK | 79.8 | 20.2 | 0.0
| MEX | 56.9 | 34.5 | 8.6
| MKK | 86.5 | 13.5 | 0.0
| TSI | 47.1 | 44.1 | 8.8
| HapMapRevision=28
}}{{PMID Auto GWAS
  |PMID=23006423
  |Trait=Response to taxane treatment (placlitaxel)
  |Title=Genetic association with overall survival of taxane-treated lung cancer patients - A genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study.
  |RiskAllele=
  |Pval=1E-6
  |OR=NR
  |ORtxt=NR
  |OA=1
}}

{{on chip | Illumina Human 1M}}